Longitudinal QT c stability and impact of baseline cardiac rhythm on discharge dose in dofetilide-treated patients

Dofetilide suppresses atrial fibrillation (AF) in a dose-dependent fashion. The protective effect of AF against QT prolongation induced torsades de pointe and transient post-cardioversion QT prolongation may result in dofetilide under-dosing during initiation. Thus, the optimal timing of cardioversi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cardiovascular electrophysiology 2022-06, Vol.33 (6), p.1281-1289
Hauptverfasser: Khan, Zeryab A, LaBreck, Megan E, Luli, Jordan, Roberts, Chelsea, Smith, Alexander, El-Zein, Rayan, Tyler, Jaret D, Fu, Eugene Y, Billakanty, Sreedhar R, Amin, Anish K, Chopra, Nagesh
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Dofetilide suppresses atrial fibrillation (AF) in a dose-dependent fashion. The protective effect of AF against QT prolongation induced torsades de pointe and transient post-cardioversion QT prolongation may result in dofetilide under-dosing during initiation. Thus, the optimal timing of cardioversion for AF patients undergoing dofetilide initiation to optimize discharge dose remains unknown as does the longitudinal stability of QT . The purpose of this study was to evaluate the impact of baseline rhythm on dofetilide dosing during initiation and assess the longitudinal stability of QT (Bazzett, Fridericia, Framingham, and Hodges) over time. Medical records of patients who underwent preplanned dofetilide loading at a tertiary care center between January 2016 and 2019 were reviewed. A total of 198 patients (66 ± 10 years, 32% female, CHADS -Vasc 3 [2-4]) presented for dofetilide loading in either AF (59%) or sinus rhythm (SR) (41%). Neither presenting rhythm, nor spontaneous conversion to SR impacted discharge dose. The cumulative dofetilide dose before cardioversion moderately correlated (r = .36; p = .0001) with discharge dose. Postcardioversion QT prolongation (p 
ISSN:1045-3873
1540-8167
DOI:10.1111/jce.15483